CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 79 enrolled
Drug / intervention
Exenatide (Bydureon®) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01928329
NCT01928329Phase 2Completed
CompareCT.gov

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

Yale University·interventional·Posted Aug 23, 2013·Updated Mar 19, 2020

In Brief

A Phase 2 clinical trial evaluating Exenatide (Bydureon®) and Placebo for Type I Diabetes. Completed, enrolled 79 participants across 8 sites.

Detailed Summary

The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType I Diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 23, 2013
Enrollment StartSep 1, 2013
Primary CompletionJun 1, 2018
Study CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.9 years ago

Interventions

Exenatide (Bydureon®)drug

Placebodrug